Knee Osteoarthritis Market Size, Trends, and Strategic Growth Analysis 2025-2032

The knee osteoarthritis industry is witnessing transformative shifts driven by innovative therapies and increasing prevalence worldwide. As new treatment modalities emerge and patient-centric approaches evolve, understanding the knee osteoarthritis market’s dynamics is crucial for anticipating future growth and challenges. This blog delves into detailed knee osteoarthritis market size, segment analysis, consumer behavior insights, key players, and strategic winning moves shaping this sector.

Market Size and Overview
The knee osteoarthritis market is estimated to be valued at USD 13.19 Bn in 2025 and is expected to reach USD 30.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.

This robust market growth is fueled by rising osteoarthritis incidence, technological breakthroughs in drug delivery systems, and increasing patient awareness. The . Knee Osteoarthritis Market  report highlights an expanding industry scope as therapeutic innovation accelerates alongside improved diagnostic tools, underpinning strong market revenue expansion.

Market Segments
The knee osteoarthritis market comprises three core segments: Treatment Type, Delivery Mode, and End-User.

- Treatment Type includes pharmaceuticals (NSAIDs, corticosteroids, viscosupplements), biologics, and surgical interventions. Biologics represent the dominant sub-segment due to efficacy in cartilage regeneration, with the fastest growth seen in viscosupplements, such as hyaluronic acid injections, exemplified by products like Taiwan Liposome Company’s TLC599 gaining traction in 2024.

- Delivery Mode covers injectable, oral, and topical therapies. Injectable treatments remain dominant given targeted therapeutic effects, while oral administration is the fastest-growing mode aligned with patient preference for ease-of-use and adherence, supported by a 2025 survey indicating a 15% increase in oral drug usage.

- End-User segments include hospitals, orthopedic clinics, and outpatient care centers. Hospitals continue leading the revenue, whereas outpatient centers demonstrate rapid growth due to shifting care patterns toward less invasive treatments.

Market Drivers
A key market driver in 2024 is the accelerating adoption of novel biologic treatments with enhanced efficacy and safety profiles. Regulatory approvals, such as Centrexion Therapeutics’ CNTX-4975 gaining FDA breakthrough status, catalyzed market growth by opening new market opportunities and encouraging R&D investments. Additionally, increasing healthcare expenditure and favorable reimbursement policies in developed economies contributed significantly to expanding the knee osteoarthritis market size and market revenue during the forecast period.

‣ Get more insights on :  Knee Osteoarthritis Market

‣ Get this Report in Japanese Language: 膝関節炎市場

‣ Get this Report in Korean Language:   무릎골관절염시장